

International CME webinar

GOOD PRACTICES FOR IMPROVING THE EFFICIENCY OF CANCER TREATMENT IN EUROPE



Dr. Eliane Kellen
Centre for Cancer Detection (CvKO)

Annemie Haelens
Belgian Cancer Registry (BCR)

Cervical cancer screening in Flanders (Belgium): opportunities & challenges

Scientific
Coordination



Under the
auspices of



Provider
and Organisation



DISCLOSURE OF INTEREST

Nothing to declare.


CERVICAL CANCER SCREENING - FLANDERS

FLANDERS 2013:

Population based organized screening program

- Age 25-64
- Invitations
- Quality monitoring

<https://baarmoederhalskanker.bevolkingsonderzoek.be/nl/professionelen>



Belgian Cancer Registry crucial in organization and evaluation



Belgian Cancer Registry

Belgium : Opportunistic screening

- 3-yearly cytology
- HPV-triage if atypical cells

Reveal the weaknesses



Translated into policy decisions

CERVICAL CANCER SCREENING - ORGANISATION

Support organisation
(exclusions - fail-safe - sensibilisation - GMD)

Quality assessment by quality indicators

Analysis screen-detected and interval
cancers / non-participants

Individual feedback reports laboratories

Invitations

Sensibilisation

Fail-safe notifications

Quality assessment by quality indicators

Belgian Cancer Registry

Reimbursement data of medical acts

GMD-GP

Cyto-histo pathology registry

Cancer Registry database



Intermutualistic
Agency

Laboratories for
pathological
anatomy

GDPR

Screening organisation



Population database resident women
Flanders age 25-64

Participation database

Fail-safe database

GMD-GP

GYN / GP
GMD-GP

Target
population

Vitalink


National
population
registry

SUPPORT ORGANISATION - INVITATIONS

Population Flanders 2020

N = 1,717,203

° 1955-1994, 25-64 years in 2020



Cancer / total hysterectomy /
no cervix



Recent cervical
sample




Never screened before

SUPPORT ORGANISATION SCREENING PROGRAM - INVITATIONS


Population Flanders 2020

N = 1,717,203
100.0 %


Invitation




Sensibilisation
(GMD-GP)
(1x/year)
(in development)



Exclusion list
(4x/year)
Most recent sample




SCREENING COVERAGE



Response rate 22.4% (2019)

Follow-up
Overscreening





Coverage 62.6%

Over screening 5.1%



- No coverage - no participation 2008-2020
- No coverage - old participation 2008-2017
- Coverage by participation in 2020 - first screening
- Coverage by participation in 2020 - subsequent screening
- Coverage by participation in 2018 and/or 2019
- Coverage by exclusion




COVERAGE IN THE AGE GROUP 25-29Y





<https://bevolkingsonderzoek.incijfers.be/>






WHO DOES NOT PARTICIPATE?

Linkage with Crossroads Bank for Social Security




- Entitled to higher reimbursement
- Not employed
- Low level of work intensity of household level

NEVER- RCT



NEVER- RCT: RESPONSE AFTER 12 MONTHS



Adapting content/lay out = limited impact

Community based sensibilisation

How can local authorities contribute to reducing barriers to participate?

= need for tailored support


7 STEPS




SCREENING RESULTS

Screening smears eligible women 2020

Abnormal smears
7.9%





Abnormal smears by lesion 2020





TREND IN INCIDENCE

Evolution incidence, Flanders, 1999-2019




Evolution age-specific incidence, Flanders 1999-2019




STAGE BY SCREENING PROFILE

- Invasive tumours, incidence years 2016-2019



FOLLOW-UP RATE BY LESION – FAIL-SAFE


- % abnormal screenings without follow-up within 12 months (screening year 2019)



Selection for fail-safe


EVALUATION FAIL-SAFE

	Number	%
Total number selected women for fail-safe	217	100.0%
Number of selected women without FUP	68	31.3%
Number of selected women with FUP	149	68.7%



EVALUATION FAIL-SAFE

	Number	%
Total number selected women for fail-safe	217	100.0%
Number of selected women without FUP	68	31.3%
Number of selected women with FUP	149	68.7%
FUP before reminder (= redundant reminders)	99	45.6%
FUP after reminder	50	23.1%



	Number	%
Number of selected women without redundant reminders	118	100.0%
Number of women without FUP	68	57.6%
Number of women with FUP after reminder	50	42.4%

CONCLUSION

Close collaboration between



&



= unique opportunities in the screening program:

- Efficient invitation system
- Detailed monitoring and quality assurance
- Tailored communication to non-attenders
- Fail-safe system

QUESTIONS?

Annemie.Haelens@kankerregister.org

Eliane.kellen@bevolkingsonderzoek.be

Acknowledgements

The screening program is funded
by the Flemish government.